Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ: SRPT )

108.41 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here?
Solid Biosciences just saw a 32% move to the upside after its trial results impressed. What's next for this firm that analysts still see massive potential in? 
Via MarketBeat
Exposures Product Safety
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
2 Growth Stocks to Buy Hand Over Fist in February
Via The Motley Fool
Sarepta Therapeutics' Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years
Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement and minimal muscle pathology progression. 
Via Benzinga
What 14 Analyst Ratings Have To Say About Sarepta Therapeutics
Via Benzinga
A Glimpse Into The Expert Outlook On Sarepta Therapeutics Through 15 Analysts
Via Benzinga
Analyst Expectations For Sarepta Therapeutics's Future
Via Benzinga
Peeling Back The Layers: Exploring Sarepta Therapeutics Through Analyst Insights
Via Benzinga
Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development
Solid Biosciences advances gene therapies for muscular and cardiac diseases, gaining FDA clearance for SGT-212 and targeting key 2025 milestones. 
Via Benzinga
Exposures Product Safety
Solid Biosciences Positioned For Next-Gen Duchenne Muscular Dystrophy Treatment Success: Analyst
Wedbush initiates Solid Biosciences with an Outperform rating, citing the potential of SGT-003 for Duchenne muscular dystrophy and a robust cash runway. 
Via Benzinga
Archer Aviation, Hims & Hers Health And Urban Outfitters Are Among Top 8 Mid-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?
8 mid-cap stocks saw impressive gains last week. Archer, Scholar Rock, Arrowhead, Iris Energy, Hims & Hers, SoundHound, Joby Aviation, and Urban Outfitters all performed well. 
Via Benzinga
Rivian Automotive, Rocket Lab And Moderna Are Among Top 10 Large-Cap Gainers Last Week (Nov 25-Nov 29): Are The Others In Your Portfolio?
Top performers last week: RIVN, RKLB, SRPT, EXAS, ESTC, ULTA, MRNA, RL, CPRT, SNAP. Any in your portfolio? Citigroup raises price target on ULTA and SNAP. 
Via Benzinga
Unveiling 15 Analyst Insights On Sarepta Therapeutics
Via Benzinga
Analyst Scoreboard: 12 Ratings For Sarepta Therapeutics
Via Benzinga
Unveiling 26 Analyst Insights On Sarepta Therapeutics
Via Benzinga
Wall Street's Top 10 Stock Calls This Week - Saturday, Nov. 30
Via Talk Markets
Topics Stocks / Equities
Arrowhead Pharmaceuticals Shares Are On The Rise Today: What's Going On?
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global licensing and collaboration agreement with Sarepta Therapeutics Inc. (NASDAQ: SRPT).... 
Via Benzinga
J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Arrowhead Launches 25% On A Massive Licensing Deal With Sarepta
The deal focuses on four clinical-stage drugs, three preclinical assets and a potential five new targets. 
Via Investor's Business Daily
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
This McKesson Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Via Benzinga
Sarepta Therapeutics (SRPT) Q3 2024 Earnings Call Transcript
SRPT earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent
Public interest groups are urging the FTC to block Novo Holdings' $16.5 billion acquisition of Catalent, citing concerns over reduced competition in critical areas like diabetes, obesity treatments,... 
Via Benzinga
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma. 
Via Investor's Business Daily
2 High-Flying Growth Stocks With Massive Upside Potential
These innovative drugmakers have potential catalysts ahead. 
Via The Motley Fool
Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics
These two could become direct competitors relatively soon. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
These 2 Biotech Stocks Are Set to Soar
Innovative drugmakers developing treatments for conditions with high unmet needs can produce lucrative wins. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS